Deal On European SPC Manufacturing Waiver Is An Acceptable Compromise

A deal on the European SPC manufacturing waiver has been agreed by the European Council, Parliament and Commission, providing a concrete path for a Regulation to move forward, albeit with compromises on several key provisions. Meanwhile, the European off-patent and brand industries remain at odds over the benefits of the waiver.

EUFlags3
The Three European Institutions Have Agreed A Compromise Deal On The SPC Waiver • Source: Shutterstock

A compromise deal reached between the European Council, Parliament and Commission on a proposed waiver for manufacturing during the term of supplementary protection certificates (SPCs) - for both export and stockpiling for ‘day-one’ launch within the European Union (EU) - has been broadly welcomed by the European off-patent industry, albeit with reservations over certain alterations that have been made to key aspects of the mechanism.

While the final version of the deal has not yet been published in full, the Commission has confirmed that the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin